Literature DB >> 29162595

Predicting Outcome in Patients with Anti-GBM Glomerulonephritis.

Emma E van Daalen1, J Charles Jennette2, Stephen P McAdoo3, Charles D Pusey3, Marco A Alba2, Caroline J Poulton4, Ron Wolterbeek5, Tri Q Nguyen6, Roel Goldschmeding6, Bassam Alchi7, Meryl Griffiths8, Janak R de Zoysa9, Beula Vincent9, Jan A Bruijn10, Ingeborg M Bajema10.   

Abstract

BACKGROUND AND OBJECTIVES: Large studies on long-term kidney outcome in patients with anti-glomerular basement membrane (anti-GBM) GN are lacking. This study aimed to identify clinical and histopathologic parameters that predict kidney outcome in these patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This retrospective analysis included a total of 123 patients with anti-GBM GN between 1986 and 2015 from six centers worldwide. Their kidney biopsy samples were classified according to the histopathologic classification for ANCA-associated GN. Clinical data such as details of treatment were retrieved from clinical records. The primary outcome parameter was the occurrence of ESRD. Kidney survival was analyzed using the log-rank test and Cox regression analyses.
RESULTS: The 5-year kidney survival rate was 34%, with an improved rate observed among patients diagnosed after 2007 (P=0.01). In patients with anti-GBM GN, histopathologic class and kidney survival were associated (P<0.001). Only one of 15 patients with a focal class biopsy sample (≥50% normal glomeruli) developed ESRD. Patients with a sclerotic class biopsy sample (≥50% globally sclerotic glomeruli) and patients with 100% cellular crescents did not recover from dialysis dependency at presentation. In multivariable analysis, dialysis dependency at presentation (hazard ratio [HR], 3.17; 95% confidence interval [95% CI], 1.59 to 6.32), percentage of normal glomeruli (HR, 0.97; 95% CI, 0.95 to 0.99), and extent of interstitial infiltrate (HR, 2.02; 95% CI, 1.17 to 3.50) were predictors of ESRD during follow-up.
CONCLUSIONS: Dialysis dependency, low percentage of normal glomeruli, and large extent of interstitial infiltrate are associated with poor kidney outcome in anti-GBM GN. Kidney outcome has improved during recent years; the success rate doubled after 2007. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2017_11_21_CJASNPodcast_18_1_v.mp3.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  ANCA; Antibodies, Antineutrophil Cytoplasmic; Autoantibodies; Biopsy; Confidence Intervals; Follow-Up Studies; Glomerular Basement Membrane; Goodpasture-s syndrome; Kidney Failure, Chronic; Multivariate Analysis; Regression Analysis; Retrospective Studies; Survival Rate; anti-GBM disease; antiglomerular basement membrane antibody; glomerulonephritis; kidney; kidney biopsy; renal dialysis

Mesh:

Substances:

Year:  2017        PMID: 29162595      PMCID: PMC5753308          DOI: 10.2215/CJN.04290417

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  20 in total

1.  Rapidly progressive crescentic glomerulonephritis.

Authors:  J Charles Jennette
Journal:  Kidney Int       Date:  2003-03       Impact factor: 10.612

2.  Spatial and Temporal Clustering of Anti-Glomerular Basement Membrane Disease.

Authors:  Mark Canney; Paul V O'Hara; Caitriona M McEvoy; Samar Medani; Dervla M Connaughton; Ahad A Abdalla; Ross Doyle; Austin G Stack; Conall M O'Seaghdha; Michael R Clarkson; Matthew D Griffin; John Holian; Anthony M Dorman; Aileen Niland; Mary Keogan; Eleanor M Wallace; Niall P Conlon; Cathal Walsh; Alan Kelly; Mark A Little
Journal:  Clin J Am Soc Nephrol       Date:  2016-07-11       Impact factor: 8.237

3.  Outcomes of patients with Goodpasture syndrome: A nationwide cohort-based study from the French Society of Hemapheresis.

Authors:  Antoine Huart; Anne-Gaëlle Josse; Dominique Chauveau; Jean-Michel Korach; Farhad Heshmati; Eric Bauvin; Olivier Cointault; Nassim Kamar; David Ribes; Jacques Pourrat; Stanislas Faguer
Journal:  J Autoimmun       Date:  2016-06-04       Impact factor: 7.094

4.  Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4.

Authors:  C O Savage; C D Pusey; C Bowman; A J Rees; C M Lockwood
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-01

5.  Anti-glomerular basement membrane disease: outcomes of different therapeutic regimens in a large single-center Chinese cohort study.

Authors:  Zhao Cui; Juan Zhao; Xiao-Yu Jia; Sai-Nan Zhu; Qi-Zhuang Jin; Xu-Yang Cheng; Ming-Hui Zhao
Journal:  Medicine (Baltimore)       Date:  2011-09       Impact factor: 1.889

6.  Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression.

Authors:  J B Levy; A N Turner; A J Rees; C D Pusey
Journal:  Ann Intern Med       Date:  2001-06-05       Impact factor: 25.391

7.  Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort.

Authors:  Bassam Alchi; Meryl Griffiths; Murugan Sivalingam; David Jayne; Ken Farrington
Journal:  Nephrol Dial Transplant       Date:  2015-01-20       Impact factor: 5.992

8.  Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome.

Authors:  C M Lockwood; A J Rees; T A Pearson; D J Evans; D K Peters; C B Wilson
Journal:  Lancet       Date:  1976-04-03       Impact factor: 79.321

9.  Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease: report of 35 cases.

Authors:  F Merkel; O Pullig; M Marx; K O Netzer; M Weber
Journal:  Nephrol Dial Transplant       Date:  1994       Impact factor: 5.992

10.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01
View more
  15 in total

Review 1.  [Rapid progressive glomerulonephritis].

Authors:  Marion Haubitz
Journal:  Internist (Berl)       Date:  2019-05       Impact factor: 0.743

2.  Anti-glomerular Basement Membrane Glomerulonephritis: A Study in Real Life.

Authors:  Marina Sánchez-Agesta; Cristina Rabasco; María J Soler; Amir Shabaka; Elisabeth Canllavi; Saulo J Fernández; Juan M Cazorla; Esperanza López-Rubio; Ana Romera; Sergio Barroso; Ana Huerta; Leonardo Calle; Milagros Sierra; Patricia Domínguez-Torres; Manuela Moreno-Ramírez; Sara Afonso; Victoria Mascarós; Armando Coca; Mario Espinosa
Journal:  Front Med (Lausanne)       Date:  2022-07-05

3.  Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study.

Authors:  Fredrik Uhlin; Wladimir Szpirt; Andreas Kronbichler; Annette Bruchfeld; Inga Soveri; Lionel Rostaing; Eric Daugas; Arnaud Lionet; Nassim Kamar; Cédric Rafat; Marek Mysliveček; Vladimír Tesař; Anders Fernström; Christian Kjellman; Charlotte Elfving; Stephen McAdoo; Johan Mölne; Ingeborg Bajema; Elisabeth Sonesson; Mårten Segelmark
Journal:  J Am Soc Nephrol       Date:  2022-03-08       Impact factor: 14.978

4.  Renal-Limited Antiglomerular Basement Membrane Disease Related To Alemtuzumab: A Case Report.

Authors:  Amye M Harrigan; Michael L West; Laurette Geldenhuys; Penelope Poyah
Journal:  Can J Kidney Health Dis       Date:  2020-10-15

Review 5.  Goodpasture's autoimmune disease - A collagen IV disorder.

Authors:  Vadim Pedchenko; A Richard Kitching; Billy G Hudson
Journal:  Matrix Biol       Date:  2018-05-12       Impact factor: 11.583

6.  Prognostic Factors in Anti-glomerular Basement Membrane Disease: A Multicenter Study of 119 Patients.

Authors:  Cindy Marques; Julien Carvelli; Lucie Biard; Stanislas Faguer; François Provôt; Marie Matignon; Jean-Jacques Boffa; Emmanuelle Plaisier; Alexandre Hertig; Maxime Touzot; Olivier Moranne; Xavier Belenfant; Djillali Annane; Thomas Quéméneur; Jacques Cadranel; Hassan Izzedine; Nicolas Bréchot; Patrice Cacoub; Alexis Piedrafita; Noémie Jourde-Chiche; David Saadoun
Journal:  Front Immunol       Date:  2019-07-18       Impact factor: 7.561

7.  Clinicopathological features and prognostic analysis of 49 cases with crescentic glomerulonephritis.

Authors:  Ting Wu; Jiajia Peng; Ting Meng; Qianqian Liu; Xiang Ao; Wei Lin; Hongling Yin; Jinbiao Chen; Jiaxi Pu; Zhangzhe Peng; Weisheng Peng; Xiaozhao Li; Xiangcheng Xiao; Qiaoling Zhou; Yong Zhong; Ping Xiao
Journal:  Exp Ther Med       Date:  2019-09-18       Impact factor: 2.447

Review 8.  [What are the indications for rescue procedures? : Systemic rheumatic diseases in the intensive care unit].

Authors:  B Hellmich; C Löffler
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

9.  Heavy chain deposition disease presenting with raised anti-GBM antibody levels; a case report.

Authors:  Michael Turner; Anna Crawford; Claire Winterbottom; Oliver Flossmann; Bassam Alchi; Maria Soares; Umanath Bhandary
Journal:  BMC Nephrol       Date:  2020-05-12       Impact factor: 2.388

10.  Severe Infection in Anti-Glomerular Basement Membrane Disease: A Retrospective Multicenter French Study.

Authors:  Pauline Caillard; Cécile Vigneau; Jean-Michel Halimi; Marc Hazzan; Eric Thervet; Morgane Heitz; Laurent Juillard; Vincent Audard; Marion Rabant; Alexandre Hertig; Jean-François Subra; Vincent Vuiblet; Dominique Guerrot; Mathilde Tamain; Marie Essig; Thierry Lobbedez; Thomas Quemeneur; Jean-Michel Rebibou; Alexandre Ganea; Marie-Noëlle Peraldi; François Vrtovsnik; Maïté Daroux; Adnane Lamrani; Raïfah Makdassi; Gabriel Choukroun; Dimitri Titeca-Beauport
Journal:  J Clin Med       Date:  2020-03-04       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.